Literature DB >> 29265013

Research on psoriasis in India: Where do we stand?

Devinder Mohan Thappa1, Malathi Munisamy1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29265013      PMCID: PMC5761022          DOI: 10.4103/ijmr.IJMR_1296_17

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
Psoriasis is a genetically determined immune-mediated inflammatory disease mediated by T-helper 1 (Th1)/Th17 T cells. With a prevalence of 0.44-2.8 per cent in India, it commonly affects individuals in their third or fourth decade with males being affected two times more common than females1. Psoriasis significantly impairs the quality of life of patients and their families resulting in great physical, emotional and social burden. It has been pointed out in the WHO's recent Global Report on Psoriasis2 that there are many unmet research gaps in psoriasis addressing various aspects such as epidemiology, aetiology, association with comorbidities, treatment and ways to improve healthcare services. It has been recommended that therapeutic researches should focus on options which can be applicable globally, on a large scale. Psoriasis is a genetically determined disease with environmental influences; ethnic differences are quite commonly expected involving all aspects of the disease from epidemiology, genetic susceptibility, clinical manifestations and response to treatment. Hence, data obtained from research done on different ethnic communities cannot be generalized globally. Hence, there is a need for research on psoriasis which is population specific or ethnicity specific. This draws attention to the status of research on psoriasis specific to the Indian population, an ethnically, genetically and culturally unique and diversified population. At present, the data on the prevalence of psoriasis are from hospital-based studies rather than from well-defined large population-based studies. There is a paucity of data related to genetics, epidemiology, disease types, associations, severity and course amongst Indian patients with psoriasis3. Only recently the research on psoriasis from India has started focusing on the genetics and epigenetics of psoriasis and association with metabolic syndrome, and there is a large gap addressing the therapeutic aspects of psoriasis, particularly on the use of biologics. Studies on risk factors that would aid in identifying preventive strategies which are crucial for chronic non-communicable diseases which lack definitive curative therapy, are barely conducted. A bibliometric study conducted on Indian psoriasis research in 20134 shows contribution of Indian researchers in the area of psoriasis. This study was undertaken to evaluate the global patterns of psoriasis literature output and to assess the contributions and impact of Indian scientists in the global psoriatic literature. The Indian researchers were ranked 11th when compared to most active countries (such as the US, UK and Germany) and were reported to actively contribute to psoriatic research as evidenced by their substantial number of publications (849 articles during 1973-2012; 2% of global production) with an overall growth rate of 127.5 per cent. International collaborative research was undertaken significantly in 2003-2012, with almost 17 countries with maximum collaboration with the US followed by the UK and Saudi Arabia4. Current research on psoriasis in India focuses on identifying human leukocyte antigen (HLA) associations and genetic polymorphisms conferring psoriatic risk amongst Indians and metabolic syndrome and cardiovascular risk amongst psoriatics5678910111213141516. We have recently reported that Th2 cytokine/regulatory T-cell gene polymorphism - interleukin-10 (IL-10) (rs1800871) polymorphism10, Th1/Th17 cytokine polymorphisms - IL-12B (rs3212227) and IL-23R (rs2201841) polymorphisms11, tumour necrosis factor alpha (TNF a) polymorphisms - TNFAIP3 (rs610604) and TNIP1 (rs17728338) polymorphisms12 confer increased risk of psoriasis, whereas Th-2 cytokine/regulatory T-cell gene polymorphism - IL-4 (rs2243250) polymorphism11 is protective against psoriasis in south Indian Tamil speaking population. Th1 pro-inflammatory cytokine genes’ IL-2 [–330 (G/T)] single nucleotide polymorphism13 was associated with greater disease severity in our population. HLA-C*06 allele was found to be positively associated with susceptibility to psoriasis, female gender and early onset of psoriasis in south Indian Tamil population14. We also observed psoriasis to be associated with significantly lowered 25-hydroxy vitamin D levels and increased levels of ischaemia-modified albumin correlating with disease severity suggesting increased systemic inflammation and oxidative stress in psoriasis15. Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation have been reported to be surrogate markers for increased cardiovascular risk in psoriasis16. The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL), the national association of Dermatologists has constituted a Special Interest Group (SIG)17 on psoriasis comprising 11 members. The SIG will work towards updating knowledge by conducting continuing medical education (CME) and publishing symposia on various aspects of psoriasis and undertaking research in psoriasis. Thus, considerable nation-wide progress is being made to improve the awareness, knowledge and research on psoriasis in India17. To conclude, despite the prevalence of psoriasis in Indian population and progress in research, India still lags behind in psoriasis research output. With the increasing prevalence and awareness of psoriasis and its association with various co-morbidities, there is ongoing need for research on various aspects of this disease related to epidemiology, aetiopathogenesis, management, co-morbidities, impact on quality of life, economic and societal burden and healthcare costs owing to the paucity of Indian data. Hence, well-conducted research in these areas specific to Indian population considering the differences in genetic makeup, environmental influences and health care costs would go a long way in improving the healthcare services for the affected patients in our country. Setting policy priorities and agenda would be the key and setting up a national research centre by the government bodies or providing funds to enhance the research in psoriasis in India would encourage researchers to continuously work on this chronic disease wherein definitive curative therapy is not available.
  14 in total

1.  Psoriasis in India: prevalence and pattern.

Authors:  Sunil Dogra; Savita Yadav
Journal:  Indian J Dermatol Venereol Leprol       Date:  2010 Nov-Dec       Impact factor: 2.545

2.  Tumor necrosis factor alpha gene promoter -238G/A polymorphism increases the risk of psoriasis vulgaris in Indian patients.

Authors:  Deepa Rajesh; Rajesh Gurumurthy; A V Moideen Kutty; Sharath Balakrishna
Journal:  Int J Dermatol       Date:  2017-01-17       Impact factor: 2.736

3.  25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity.

Authors:  L Chandrashekar; G R Krishna Kumarit; M Rajappa; G Revathy; M Munisamy; D M Thappa
Journal:  Br J Biomed Sci       Date:  2015       Impact factor: 3.829

4.  Metabolic Syndrome in Psoriasis among Urban South Indians: A Case Control Study Using SAM-NCEP Criteria.

Authors:  Banavasi S Girisha; Neetha Thomas
Journal:  J Clin Diagn Res       Date:  2017-02-01

5.  TNFAIP3 and TNIP1 polymorphisms confer psoriasis risk in South Indian Tamils.

Authors:  S Indhumathi; M Rajappa; L Chandrashekar; P H Ananthanarayanan; D M Thappa; V S Negi
Journal:  Br J Biomed Sci       Date:  2015       Impact factor: 3.829

6.  The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in South Indian Tamils.

Authors:  S Indhumathi; Medha Rajappa; Laxmisha Chandrashekar; P H Ananthanarayanan; D M Thappa; V S Negi
Journal:  Arch Dermatol Res       Date:  2016-01-21       Impact factor: 3.017

7.  Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: A hospital-based cross-sectional study.

Authors:  Sunil K Kothiwala; Neena Khanna; Nikhil Tandon; Nitish Naik; Vinod K Sharma; Sanjeev Sharma; V Sreenivas
Journal:  Indian J Dermatol Venereol Leprol       Date:  2016 Sep-Oct       Impact factor: 2.545

8.  Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra.

Authors:  Aarti Sudam Salunke; Mahendra Vinayak Nagargoje; Vasudha Abhijit Belgaumkar; Sunil Narayan Tolat; Ravindranath Brahmadev Chavan
Journal:  J Clin Diagn Res       Date:  2017-08-01

9.  Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.

Authors:  Sunil Dogra; Rahul Mahajan
Journal:  Indian Dermatol Online J       Date:  2016 Nov-Dec

10.  Relationship between psoriasis and non-alcoholic fatty liver disease.

Authors:  Krishnasamy Narayanasamy; Abarna Devi Sanmarkan; Karthick Rajendran; Chezhian Annasamy; Senthilkumar Ramalingam
Journal:  Prz Gastroenterol       Date:  2016-02-26
View more
  3 in total

1.  Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study.

Authors:  Rajasekar Seetharaman; Anjum Mahmood; Prashant Kshatriya; Divyang Patel; Anand Srivastava
Journal:  Case Rep Dermatol Med       Date:  2019-05-02

2.  Potential implications of Ayurveda in Psoriasis: A clinical case study.

Authors:  Guruprasad C Nille; Anand Kumar Chaudhary
Journal:  J Ayurveda Integr Med       Date:  2021-02-03

3.  Active Cousinia thomsonii Extracts Modulate Expression of Crucial Proinflammatory Mediators/Cytokines and NFκB Cascade in Lipopolysaccharide-Induced Albino Wistar Rat Model.

Authors:  Khalid Bashir Dar; Ishfaq Shafi Khan; Shajrul Amin; Aijaz Hassan Ganie; Aashiq Hussain Bhat; Showkat Ahmad Dar; Bilal Ahmad Reshi; Showkat Ahmad Ganie
Journal:  J Inflamm Res       Date:  2020-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.